COVID-19 and Disease Tolerance
Dr. Irah King discusses disease tolerance in light of the recent COVID-19 pandemic and why some weather the infection unscathed
Maziar Divangahi
View his faculty profile here: Maziar Divangahi, PhD
Professor, Department of Medicine, McGill University
Associate Director, Meakins-Christie Laboratories
Research Theme: Host defense against pulmonary pathogens; regulation of death program in macrophages
Keywords: innate and adaptive immunity • influenza virus • mycobacterium tuberculosis • cell death program
View Maziar Divangahi’s recent posts and news below.
Defeating SARS-CoV-2: A Team Effort
Dr. Maziar Divangahi asserts that only a team effort across scientific disciplines will lead to the elimination of SARS-CoV-2.
Using β-glucan to Help Fight TB Infection
Dr. Nargis Khan and Dr. Eva Kaufmann from the Divangahi lab publish their work in Cell Reports
Five CIHR Project Grants Awarded!
Congratulations to all Meakins and RECRU members who were funded in the Fall 2019 Project Grant Competition!
Grant to Investigate HSCs & Innate Immunity
Maziar Divangahi receives funding from the Bill & Melinda Gates Foundation.
Meakins Faculty Delegation to Braunschweig
Meakins faculty visit the Helmholtz Centre for Infection Research in Braunschweig
2019 MGH Foundation Research Awards
RESP Program researchers are among the recipients of the Montreal General Hospital Foundation’s 2019 Research Awards
Flu Treatment Using Lipid Target
Lipid mediator Leukotriene B4 is capable of reducing tissue damage from the flu
Anti-TB Drugs can Increase Risk of TB Re-Infection
Vulnerability of the host to Mycobacterium tuberculosis infection is due to a compromised gut microbiota
Beyond Killing Tuberculosis
Publication by Maziar Divangahi and Nargis Khan in Science Immunology